Daxor Corporation (DXR) Stock Analysis & Investment Frameworks
Daxor Corporation (DXR) stock analysis on Invetso. Review Daxor Corporation’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Daxor Corporation Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Medical - Instruments & Supplies
- Country: US
Daxor Corporation Key Financial Metrics
- Market Cap: $49.83M
- Revenue: $503424.00
- P/E Ratio: 5.44
- ROE: 12.75%
- ROIC: 12.02%
- Dividend Yield: N/A
About Daxor Corporation
Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.
Daxor Corporation Investment Frameworks
Invetso analyzes Daxor Corporation (DXR) across the following frameworks:
- Daxor Corporation 10Y Growth Potential
- Daxor Corporation Scenario Analysis
- Daxor Corporation Risks & Opportunities
- Daxor Corporation Economic Moat
- Daxor Corporation Business Model
- Daxor Corporation Management
- Daxor Corporation SWOT Analysis
- Daxor Corporation Porter's 5 Forces
- Daxor Corporation PESTLE Analysis
- Daxor Corporation ESG Analysis